Drug sales surge in the Southeast during winter, according to pharmaceutical sources
In anticipation of the upcoming winter season, Cimed, the third-largest pharmaceutical company in the country by sales volume, is gearing up for increased demand for its winter medication lines. The company's focus is on key products such as Cimegripe, Loratamed, Nimesulida, Ciflogex, Ambroxmel, Alergomine, Fexx, and Narix, which are expected to drive sales.
The significant increase in demand is linked to lower temperatures, decreased air humidity, and increased circulation of respiratory viruses. These brands encompass a variety of medications, including anti-flu, analgesics, antipyretics, expectorants, syrups, vitamins, immunomodulators, and antihistamines.
Cimed is taking proactive measures to address the seasonal impact. The company has reinforced its logistical operation and stock in key regions to ensure smooth distribution of its products. Historically, the majority of winter medication consumption has occurred in the South and Southeast regions.
To meet the growing demand, Cimed has expanded its factory in Pouso Alegre to increase production capacity for its winter portfolio. The company plans ahead to maintain market demand, selling an estimated 64 million units in the Southeast, which is 50% of the total volume expected nationwide.
Cimed's winter portfolio includes over 65 brands of over-the-counter and generic medications. In 2024, the company's winter sales generated R$ 1 billion nationwide, with the Southeast contributing R$ 520 million, accounting for 52% of the national total.
João Adibe Marques, president of Cimed, explains that the company's strategic planning and expansion have provided them with the speed to keep up with and meet market demand. The company has ensured special preparation to meet the increased demand, with a focus on robust production, logistics, and portfolio planning.
While specific forecasts for Cimed's winter revenue for the Southeast region in 2025 are not publicly available, it is clear that the company is well-prepared for the upcoming winter season. For detailed financial and product line forecasts, it is recommended to consult Cimed's official financial reports, investor relations releases, or industry market research reports specializing in pharmaceuticals for the 2025 period.
Cimed recognizes the importance of health and wellness during the winter season, particularly in managing medical-conditions and respiratory-conditions. To support this, the company has expanded its focus on its winter portfolio, which includes over 65 brands of over-the-counter and generic medications. Furthermore, to ensure the availability of these products, Cimed has increased its production capacity through factory expansions and reinforced logistical operations in key regions.
